MYL - Mylan N.V.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
17.26
-0.01 (-0.06%)
At close: 4:00PM EST

17.36 +0.10 (0.58%)
After hours: 7:37PM EST

Stock chart is not supported by your current browser
Previous Close17.27
Open17.15
Bid17.34 x 4000
Ask17.36 x 4000
Day's Range16.87 - 17.33
52 Week Range16.63 - 35.45
Volume6,222,019
Avg. Volume5,829,132
Market Cap8.776B
Beta (3Y Monthly)1.76
PE Ratio (TTM)191.78
EPS (TTM)0.09
Earnings DateNov. 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2007-06-27
1y Target Est25.81
  • Bloomberg

    Biogen Sheds $3 Billion in Value on Top Drug’s Patent Review

    (Bloomberg) -- Biogen Inc. shed more than $3 billion in market value in the past two trading sessions as a patent review of its top drug Tecfidera Wednesday raised concerns over a potential generic threat from Mylan NV.Shares fell as much as 3.7% on Thursday, the most in two months, extending losses for a third day. Analysts held different views on the trial, with Evercore ISI Umer Raffat saying the hearing went better-than-expected for Biogen, while RBC analyst Brian Abrahams said Mylan seemed to make “a slightly stronger case.”“In totality, the arguments and judges’ reactions seemed to favor MYL incrementally,” he wrote to clients, assigning a 60% probability of success for the company.On Wednesday, the U.S. Patent and Trial Appeal Board heard arguments under a process called inter partes review on Mylan’s challenge of Biogen patent 8,399,514. The generic drugmaker contends that the active ingredient in Tecfidera, dimethyl fumarate, had been known for years and the dosage form was predictable.The stakes are high for Cambridge, Massachusetts-based Biogen. The multiple sclerosis drug is its top-selling medicine, generating $1.1 billion in sales just last quarter. The patent is critical in extending the medicine’s exclusivity into the next decade as it’s set to expire in 2028. All the other Tecfidera patents listed on the FDA’s registry of information expire by June 2020.\--With assistance from Susan Decker.To contact the reporter on this story: Tatiana Darie in New York at tdarie1@bloomberg.netTo contact the editors responsible for this story: Catherine Larkin at clarkin4@bloomberg.net, Debarati RoyFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Thomson Reuters StreetEvents

    Edited Transcript of MYL earnings conference call or presentation 5-Nov-19 3:00pm GMT

    Q3 2019 Mylan NV Earnings Call

  • Top-Ranked Nasdaq-100 ETF at New High: 5 Best Stocks
    Zacks

    Top-Ranked Nasdaq-100 ETF at New High: 5 Best Stocks

    Likelihood of a soon-to-be-signed U.S.-China trade deal, upbeat holiday season sales expectations and decent earnings have led the Nasdaq-100 ETF to a new high.

  • Business Wire

    Mylan and Pfizer Announce Viatris as the New Company Name in the Planned Mylan-Upjohn Combination

    Mylan N.V. (MYL) and Pfizer Inc. (PFE) today announced that the name of the new company to be formed by the planned combination of Mylan and Upjohn, a division of Pfizer, will be Viatris (pronounced ‘viǝ-trīs). Deriving its name from Latin, Viatris embodies the new company’s goal of providing a path—“VIA”—to three—“TRIS”—core goals: expanding access to medicines, leading by innovating to meet patient needs, and being a trusted partner for the healthcare community worldwide. “The name Viatris communicates the strength of our companies’ combined heritage and our shared goal to provide the highest-quality medicines to the most patients possible,” said Michael Goettler, Group President, Upjohn, who will serve as Chief Executive Officer of Viatris, as previously announced.

  • Teva (TEVA) Q3 Earnings Miss, Stock Up on Guidance Increase
    Zacks

    Teva (TEVA) Q3 Earnings Miss, Stock Up on Guidance Increase

    Teva Pharmaceutical (TEVA) misses earnings estimate but beats the same for sales. The company increases the lower end of its 2019 sales and earnings guidance. Shares rise.

  • GlobeNewswire

    EQUITY ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Mylan N.V.

    NEW YORK, Nov. 07, 2019 -- Levi & Korsinsky notifies investors that it has commenced an investigation of Mylan N.V. (“Mylan” or “the Company”) (NASDAQ: MYL) concerning.

  • Theravance (TBPH) Q3 Loss In Line, Revenues Lag Estimates
    Zacks

    Theravance (TBPH) Q3 Loss In Line, Revenues Lag Estimates

    Theravance's (TBPH) third-quarter loss matches estimates while revenues miss the same in absence of product sales due to the sale of its only marketed drug Vibativ to Cumberland Pharmaceuticals.

  • Acorda (ACOR) Q3 Earnings and Revenues Surpass Estimates
    Zacks

    Acorda (ACOR) Q3 Earnings and Revenues Surpass Estimates

    Acorda (ACOR) posts narrower-than-expected loss with revenues also topping estimates in the third quarter. Inbrija is also off to a promising start with sales rising sequentially.

  • Mylan's (MYL) Q3 Earnings Beat Estimates, Revenues Miss
    Zacks

    Mylan's (MYL) Q3 Earnings Beat Estimates, Revenues Miss

    Mylan's (MYL) earnings beat estimates but sales miss the same in the third quarter of 2019. The company updates guidance for 2019.

  • US STOCKS-Wall St set to open higher as trade optimism builds
    Reuters

    US STOCKS-Wall St set to open higher as trade optimism builds

    Wall Street was set to open higher for the fifth straight session on Tuesday, a day after all three major U.S. stock indexes closed at record highs on rising hopes of a trade truce between Washington and Beijing. China is pushing President Donald Trump to remove more tariffs as part of the "phase one" deal, which may be signed this month, according to the latest reports. Trade-sensitive chipmakers, including Advanced Micro Devices Inc and Nvidia Corp, rose between 0.5% and 1.3% in premarket trading.

  • Mylan (MYL) Q3 Earnings Surpass Estimates
    Zacks

    Mylan (MYL) Q3 Earnings Surpass Estimates

    Mylan (MYL) delivered earnings and revenue surprises of 2.63% and -2.39%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Mylan shares slide after warning of hit to revenue
    Reuters

    Mylan shares slide after warning of hit to revenue

    Mylan, which posted higher-than-expected third-quarter profit with the help of cost constraints, said it would reassess products it sells outside United States and had nearly completed its review of U.S. products. The review process should not affect net profit, President Rajiv Malik said on a conference call with analysts. Mylan in July agreed to merge with Pfizer Inc's Upjohn unit that sells off-patent branded drugs.

  • Mylan Earnings Beat, Revenue Misses In Q3
    Investing.com

    Mylan Earnings Beat, Revenue Misses In Q3

    Investing.com - Mylan reported third quarter earnings that beat analysts' expectations on Tuesday and revenue that fell short of forecasts.

  • Investing.com

    Day Ahead: Top 3 Things to Watch

    Investing.com - Here's a preview of the top 3 things that could rock markets tomorrow.

  • Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More
    Zacks

    Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More

    Let us take a look at five drug/biotech companies, which are supposed to release their quarterly results on Nov 5.

  • Should You Buy Mylan (MYL) Ahead of Earnings?
    Zacks

    Should You Buy Mylan (MYL) Ahead of Earnings?

    Mylan (MYL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • Glaxo (GSK) Beats Q3 Earnings Estimates, Raises '19 EPS View
    Zacks

    Glaxo (GSK) Beats Q3 Earnings Estimates, Raises '19 EPS View

    Glaxo (GSK) beats on earnings and sales in the third quarter. Strong growth of vaccine and respiratory portfolio boosts sales. However, Advair generic severely impacts the drug's U.S. sales.

  • Mylan (MYL) to Report Q3 Earnings: What's in the Offing?
    Zacks

    Mylan (MYL) to Report Q3 Earnings: What's in the Offing?

    Investors will look forward to regular top and bottom-line numbers, when Mylan (MYL) reports Q3 results along with updates on merger with Upjohn.

  • Mylan (MYL) Expected to Beat Earnings Estimates: Should You Buy?
    Zacks

    Mylan (MYL) Expected to Beat Earnings Estimates: Should You Buy?

    Mylan (MYL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Pfizer (PFE) Rises on Q3 Earnings & Sales Beat, Ups EPS View
    Zacks

    Pfizer (PFE) Rises on Q3 Earnings & Sales Beat, Ups EPS View

    Pfizer (PFE) beats estimates for third-quarter earnings and sales and raises earnings guidance range for 2019 while tightening revenue outlook.

  • GlobeNewswire

    Mapi Announces First Patient Enrolled in the Phase III Clinical Trial of GA Depot for Relapsing Multiple Sclerosis (RMS)

    Glatiramer acetate, the active material of Copaxone®, or its generic forms, is the most common treatment for RMS in the US. GA Depot is a long-acting depot formulation injection of glatiramer acetate administered once every four weeks, compared with the daily or thrice weekly regimen used with Copaxone® or its generic forms.

  • Acorda (ACOR) to Post Q3 Earnings: What's in the Cards?
    Zacks

    Acorda (ACOR) to Post Q3 Earnings: What's in the Cards?

    During Acorda's (ACOR) third-quarter earnings call, investor focus will be on the sales uptick of its newly launched Parkinson's disease drug Inbrija.

  • Pfizer (PFE) to Report Q3 Earnings: What's in the Cards?
    Zacks

    Pfizer (PFE) to Report Q3 Earnings: What's in the Cards?

    While Pfizer's (PFE) key drugs like Ibrance, biosimilars and strong emerging market sales are likely to have driven Q3 sales, genericization of some older drugs are likely to have hurt the same.

  • Why the Earnings Surprise Streak Could Continue for Mylan (MYL)
    Zacks

    Why the Earnings Surprise Streak Could Continue for Mylan (MYL)

    Mylan (MYL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • Theravance Pipeline Strong, Dependence on Yupelri a Concern
    Zacks

    Theravance Pipeline Strong, Dependence on Yupelri a Concern

    Theravance's (TBPH) newly-launched COPD drug Yupelri is witnessing a solid adoption while its pipeline programs are also progressing well. However, excessive reliance on Yupelri for revenues is a woe.